+Compare
IBIO
Stock ticker: ASE
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
8.5M

IBIO iBio Forecast, Technical & Fundamental Analysis

a company which engages in the development and commercialization of vaccines and therapeutic proteins

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for IBIO with price predictions
08:00 PM EDT Oct 02, 2023

IBIO's RSI Indicator climbs out of oversold territory

The RSI Oscillator for IBIO moved out of oversold territory on September 12, 2023. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 46 similar instances when the indicator left oversold territory. In of the 46 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where IBIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IBIO just turned positive on September 08, 2023. Looking at past instances where IBIO's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IBIO advanced for three days, in of 181 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 26, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on IBIO as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IBIO broke above its upper Bollinger Band on September 13, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IBIO entered a downward trend on September 15, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.552) is normal, around the industry mean (22.791). P/E Ratio (117.647) is within average values for comparable stocks, (131.379). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.084). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (1.033) is also within normal values, averaging (309.467).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.17B. The market cap for tickers in the group ranges from 402 to 403.32B. NVO holds the highest valuation in this group at 403.32B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was 16%, and the average quarterly price growth was 21%. BNOX experienced the highest price growth at 337%, while RGMP experienced the biggest fall at -72%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was 139% and the average quarterly volume growth was 150%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 70
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published General Information

General Information

a company which engages in the development and commercialization of vaccines and therapeutic proteins

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
8800 HSC Parkway
Phone
+1 302 355-0650
Employees
23
Web
https://www.ibioinc.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OVV45.810.03
+0.07%
Ovintiv
JRVR15.09-0.12
-0.79%
James River Group Holdings Ltd
PRGS51.47-0.71
-1.36%
Progress Software Corp
CYCN3.21-0.14
-4.16%
Cyclerion Therapeutics
CLPT4.57-0.23
-4.79%
ClearPoint Neuro

IBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBIO has been loosely correlated with VOR. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if IBIO jumps, then VOR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBIO
1D Price
Change %
IBIO100%
-1.82%
VOR - IBIO
36%
Loosely correlated
+5.63%
REPL - IBIO
31%
Poorly correlated
+2.47%
ADMA - IBIO
31%
Poorly correlated
-5.52%
MRTX - IBIO
31%
Poorly correlated
+3.95%
ENSC - IBIO
31%
Poorly correlated
-5.26%
More